Inside Moderna’s Biggest mRNA Test Since COVID

Name: Inside Moderna’s Biggest mRNA Test Since COVID
Uploaded: 2026-09-02T07:31:14-07:00
Duration: 38 min 30 s
Channel: a16z
Description: Moderna has achieved a historic breakthrough with its personalized mRNA cancer vaccine (mRNA-4157/V940), demonstrating superior recurrence-free survival…

a16z

00:38:30 Summary & quotes Report Issue

Loading transcript... Click for full transcript

About this episode Moderna has achieved a historic breakthrough with its personalized mRNA cancer vaccine (mRNA-4157/V940), demon… AI summary

Moderna has achieved a historic breakthrough with its personalized mRNA cancer vaccine (mRNA-4157/V940), demonstrating superior recurrence-free survival compared to Keytruda alone in a Phase 3 melanoma trial. The technology leverages synthetic, enzymatic manufacturing to create custom vaccines based on individual tumor mutations within ~42 days, overcoming previous failures in cancer vaccines through precise personalization. The company is now expanding this platform to lung, kidney, and 'cold' tumors like pancreatic cancer, while also exploring applications in autoimmune diseases.

Key takeaways 5

Moderna's mRNA cancer vaccine (mRNA-4157/V940) combined with Merck's Keytruda achieved a primary endpoint of recurrence-free survival in a Phase 3 melanoma trial, marking the first time a cancer vaccine has shown efficacy better than checkpoint inhibitors alone.
The technology uses a personalized approach: sequencing both tumor and healthy DNA to identify unique mutations, then using an algorithm to select the 34 most relevant neoantigens to create a custom mRNA vaccine for each patient.
The manufacturing process is fully synthetic and enzymatic, allowing for a 'needle-to-needle' turnaround time of approximately 42 days, which is significantly faster and more scalable than the ex vivo cell processing required for CAR-T therapies.
The regulatory pathway is established as a Process BLA (Biologics License Application) rather than a Product BLA, similar to CAR-T, because every dose is unique; the FDA regulates the robustness and reproducibility of the manufacturing process itself.
The platform is expanding beyond melanoma to lung cancer (Phase 3), kidney/bladder cancer (Phase 2), and 'cold' tumors like pancreatic and gastric cancer where checkpoint inhibitors currently fail, leveraging the orthogonal mechanism of action.

Notable quotes 4 AI-generated: wording and quote attribution may be wrong. Use the play link to verify.

“"It's the first time there is a cancer vaccine working. The field has been doing that for 20 plus years, more than a thousand clinical trials that have all failed."”

▶ 0:00 Highlights the historical significance and breakthrough nature of Moderna's success in oncology after decades of failure in the field.
“"Kudra... is basically a molecule that basically open the gates for letting the dogs out... Moderna product is able at the molecular level inside your immune system to very specifically teach your T-cell this is what you need to look for."”

Provides a clear analogy distinguishing the non-specific mechanism of checkpoint inhibitors from the targeted teaching mechanism of mRNA vaccines.
“"In tisan [Intarain] which is Moderna medicine is going to be used with Keytruda... it might be used early in diseases where Keytruda doesn't work... or with other agents... those are very orthogonal mechanism of action."”

Outlines the strategic vision for integrating the vaccine into various treatment paradigms, from combination therapy to monotherapy in early-stage disease.
“"The current version of Intarain which Moderna is... is the worst version of Intarain you're going to see for the rest of medical history."”

▶ 17:28 Stefan Bonsel expresses extreme confidence in the platform's potential for improvement, comparing it to early AI models that have since evolved significantly.